Puerarin
(Synonyms: 葛根素) 目录号 : GN10680
Puerarin是一种从葛根中提取的植物雌激素,对心血管系统具有保护功能。
Cas No.:3681-99-0
Sample solution is provided at 25 µL, 10mM.
Puerarin is a phytoestrogen extracted from Pueraria lobata with protective functions on the cardiovascular system[1]. Puerarin exerts vasodilator effects on rat thoracic aorta by activating large conductance voltage-activated and calcium-activated potassium channels (BKCa)[2]. Puerarin has been widely used to delay the progression of hepatitis, liver fibrosis, and non-alcoholic fatty liver disease in animal models of liver disease[3].
In vitro, Puerarin treatment for 24 hours significantly inhibited the activity of SH-SY5Y cells with an IC50 value of 174.4μM[4]. Treatment of U251 and U87 cells with 200μM Puerarin for 48 hours significantly inhibited cell proliferation, induced cell apoptosis, and promoted the expression of Bax and cleaved caspase-3[5]. Puerarin treatment (20μM) for 48 hours promoted the proliferation of MC3T3-E1 cells, increased alkaline phosphatase (ALP) activity, and up-regulated the expression of osteogenesis-related proteins[6].
In vivo, Puerarin treatment (80mg/kg/day; i.p.) for three months improved myocardial structure and function, alleviated cardiac morphological disorder and collagen fiber proliferation in spontaneously hypertensive rats[7]. Oral administration of Puerarin (100mg/kg/day) for 28 days ameliorated Aβ(1-42) -induced cognitive impairment and reversed hippocampal cell apoptosis in rats[8]. Daily intraperitoneal injection of Puerarin (100mg/kg/day) for 13 weeks prevented high-fat diet (HFD)-induced obesity and steatosis in mice, significantly altered the composition of gut microbiota, and greatly increased the abundance of Akkermansia muciniphil [9].
References:
[1] Shu-Yong W E I, Yi C, Xiao-Yu X U. Progress on the pharmacological research of puerarin: a review[J]. Chinese Journal of Natural Medicines, 2014, 12(6): 407-414.
[2] Zhou Y X, Zhang H, Peng C. Puerarin: a review of pharmacological effects[J]. Phytotherapy Research, 2014, 28(7): 961-975.
[3] Wang D, Bu T, Li Y, et al. Pharmacological activity, pharmacokinetics, and clinical research progress of puerarin[J]. Antioxidants, 2022, 11(11): 2121.
[4] Sui X, Liu T, Zou Z, et al. Effects and mechanisms of puerarin against neuroblastoma: insights from bioinformatics and in vitro experiments[J]. BMC Complementary Medicine and Therapies, 2024, 24(1): 257.
[5] Yang J A, Li J Q, Shao L M, et al. Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines[J]. International journal of clinical and experimental medicine, 2015, 8(6): 10132.
[6] Wang N, Wang X, Cheng W, et al. Puerarin promotes osteogenesis and inhibits adipogenesis in vitro[J]. Chinese Medicine, 2013, 8(1): 17.
[7] Yan J, Honglei Y, Yun W, et al. Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway[J]. European Journal of Pharmacology, 2022, 933: 175254.
[8] Li J, Wang G, Liu J, et al. Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo[J]. European Journal of Pharmacology, 2010, 649(1-3): 195-201.
[9] Wang L, Wu Y, Zhuang L, et al. Puerarin prevents high-fat diet-induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice[J]. PLoS One, 2019, 14(6): e0218490.
Puerarin是一种从葛根中提取的植物雌激素,对心血管系统具有保护功能[1]。Puerarin通过激活高电导电压和钙激活钾通道(BKCa)对大鼠胸主动脉产生血管舒张作用[2]。Puerarin广泛应用于肝病动物模型中延缓肝炎、肝纤维化和非酒精性脂肪肝的进展[3]。
在体外,Puerarin处理24小时可显著抑制SH-SY5Y细胞活性,IC50值为174.4μM[4]。200μM的Puerarin处理U251和U87细胞48小时能抑制细胞增殖、诱导凋亡,并促进Bax和cleaved caspase-3表达[5]。20μM的Puerarin处理MC3T3-E1细胞48小时可促进细胞增殖,提高碱性磷酸酶(ALP)活性,并上调成骨相关蛋白表达[6]。
在体内,自发性高血压大鼠每日腹腔注射Puerarin(80mg/kg/day;持续三个月)可改善心肌结构和功能,减轻心脏形态紊乱和胶原纤维增生[7]。大鼠每日口服100mg/kg/day剂量的Puerarin(持续28天)能改善Aβ(1-42)诱导的认知障碍并逆转海马细胞凋亡[8]。小鼠每日腹腔注射100mg/kg/day剂量的Puerarin(持续13周)可预防高脂饮食(HFD)诱导的肥胖和脂肪变性,显著改变肠道菌群组成并大幅提高Akkermansia muciniphila丰度[9]。
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells |
Preparation Method | SH-SY5Y cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO2, and passaged when the cell confluence reached 90%. SH-SY5Y cells were seeded in 96-well plates at a density of 5×103 cells/well and cultured in complete medium for 24h. Subsequently, Puerarin was added to the medium so that the final concentration of Puerarin was 0, 25, 50, 75, 100, 150, and 200μM, and the culture was continued for 24h. 10μl CCK-8 solution was added to each well and incubated for 2h at 37°C. The absorbance at 450nm was measured using a microplate reader. |
Reaction Conditions | 0, 25, 50, 75, 100, 150, and 200μM; 24h |
Applications | Puerarin significantly inhibited the viability of SH-SY5Y cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male spontaneously hypertensive rats |
Preparation Method | Thirty male specific pathogen-free (SPF) spontaneously hypertensive rats (SHR) were housed in SPF-grade animal centers under a 12h-12h light-dark cycle with ad libitum access to food and water. After acclimatization for one week, 30 rats were randomly divided into 2 groups: SHR group (saline treatment); SHR+Puerarin group (Puerarin treatment at 80mg/kg/day; i.p.). The experimental period was 3 months, after which the cardiac function of the rats was analyzed. |
Dosage form | 80mg/kg/day for 3 months; i.p. |
Applications | Puerarin treatment improved myocardial structure and function, ameliorated cardiac morphological disorder and collagen fiber proliferation in rats. |
References: | |
| Cas No. | 3681-99-0 | SDF | |
| 别名 | 葛根素 | ||
| 化学名 | 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one | ||
| Canonical SMILES | C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O | ||
| 分子式 | C21H20O9 | 分子量 | 416.38 |
| 溶解度 | DMF: 16 mg/ml,DMSO: 12.5 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 0.25 mg/ml | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4017 mL | 12.0083 mL | 24.0165 mL |
| 5 mM | 480.3 μL | 2.4017 mL | 4.8033 mL |
| 10 mM | 240.2 μL | 1.2008 mL | 2.4017 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
